Entry
Reader's guide
Entries A-Z
Subject index
Antipsychotic Drugs
Antipsychotics are medications that target psychotic symptoms such as delusions and hallucinations. These medications, also known as neuroleptics or major tranquilizers, are also commonly used as mood stabilizers and for nonspecific sedation. The array of antipsychotics is expanding, as new agents are developed with wider applications than those of the older medications. Many substances can produce psychosis, which is often treated with antipsychotic drugs. With one notable exception, antipsychotic drugs have little abuse potential.
Psychosis is defined by Stedman's Medical Dictionary as "a mental and behavioral disorder causing gross distortion or disorganization of a person's mental capacity, affective response, and capacity to recognize reality, communicate, and relate to others." All antipsychotics treat psychosis by blocking postsynaptic dopamine (D2) receptors in the brain. Antipsychotic efficacy appears to occur in a window of 60% to 80% D2 receptors blockade. Antagonism below 60% confers less antipsychotic effect, whereas blockade of more than 80% of the receptors produces extrapyramidal symptoms.
There are two categories of antipsychotics, typical and atypical, which differ by their receptor activities. These categories are also known as first generation and second generation antipsychotics. In addition to D2 blockade, atypical antipsychotics are active at serotonin receptors (5-HT2) and other dopamine receptor subtypes. Atypical agents are thought to bind less tightly to D2 receptors and occupy these receptors more intermittently than do typical antipsychotics. These variations explain the differences in therapeutic effects and side effects, which may be more benign in the atypical drugs. Other important distinguishing factors between these two classes include cost and Food and Drug Administration (FDA)-approved indications. The atypical agents are newer and much more expensive than the typical agents. The atypical agents have FDA indications as mood stabilizers and are used to treat acute mania and depression and to provide maintenance in bipolar disorder.
Representative Antipsychotics
Typical Antipsychotics
- Chlorpromazine (Thorazine)
- Haloperidol (Haldol and Haldol decanoate)
- Fluphenazine (Prolixin and Prolixin decanoate)
- Perphenazine (Trilafon)
- Thioridazine (Mellaril)
- Thiothixene (Navane)
- Pimozide (Orap)
Atypical
- Clozapine (Clozaril)
- Risperidone (Risperdal)
- Olanzapine (Zyprexa)
- Quetiapine (Seroquel)
- Ziprasidone (Geodon)
- Aripiprazole (Abilify)
Side Effects
Antipsychotic medications can produce side effects that range from uncomfortable to life threatening. Some side effects are specific to a single drug. Other side effects are class effects that can occur from any drug in the class. A 2006 study by the National Institute of Mental Health compared the effectiveness and tolerability of the older typical antipsychotics and the newer atypical medications. Many were surprised by the outcome: Three quarters of study patients discontinued the use of a prescribed antipsychotic because of side effects or perceived lack of efficacy. In addition, the older medication, perphenazine, appeared to offer benefits and tolerability comparable to the newer medications. Clozapine stands out among all of the antipsychotics as having more efficacy, especially in treating people with schizophrenia that have not responded to other medications. Clozapine also carries unique risks that require close monitoring.
Generic Side Effects
Extrapyramidal side effects result from the dopamine receptor blockade in brain areas that influence muscle movement and tone. These side effects can present as an acute dystonic reaction, muscle stiffness, tremor, shuffling gait, and flattened facial expression. Acute dystonic reactions are sustained muscle contractions that can be painful and frightening but are very treatable. Extrapyramidal side effects are most common in typical antipsychotics, especially the more potent medications such as haloperidol. Often extrapyramidal symptoms improve with medications such as benztropine (Cogentin). Tardive dyskinesia is a potentially disabling tic disorder that results from exposure to antipsychotics, especially older medications.
...
- Behavioral Addictions
- Classifications of Drugs of Abuse
- Alcohol
- Amphetamines
- Amyl Nitrite
- Anabolic Steroids
- Anxiolytic Drugs
- Barbiturates
- Benzodiazepines
- Buprenorphine
- Caffeine
- Central Nervous System Depressants
- Central Nervous System Stimulants
- Club Drugs
- Cocaine and Crack
- Drugs, Classification of
- Ecstasy
- Fentanyl
- Hallucinogens
- Heroin
- Illicit and Illegal Drugs
- Inhalants
- Levo-Alpha Acetyl Methadol
- Marijuana
- Methadone
- Methamphetamine
- Methods of Drug Administration
- Morphine
- Naltrexone
- Opioids
- Over-the-Counter Drugs
- OxyContin
- Prescription Drugs
- Tobacco
- Criminal Justice System and Substance Abuse
- Engagement and Intervention
- Family and Community Issues
- Adult Children of Alcoholics
- Al-Anon
- Alateen
- Behavioral Couples Therapy
- Binge Drinking
- Brief Strategic Family Therapy
- Children of Alcoholics
- Codependency
- Community Reinforcement and Family Training
- Community Reinforcement Approach
- Enabling
- Experimental Substance Use
- Family Behavior Therapy
- Family Therapy
- Fetal Alcohol Syndrome
- Fetal Effects of Alcohol and Other Drugs
- Multidimensional Family Therapy
- Violence, Intimate Partner and Substance Abuse Treatment
- Models of Addiction
- Neurobiology of Addiction
- Prevention Theories, Research, Techniques, Strategies, and Effectiveness
- Alcohol Marketing
- Alternative Activities
- Behavioral Risk Factor Surveillance System
- Community-Based Processes
- Drug Abuse Resistance Education
- Environmental Approaches
- Evidence-Based Prevention
- Evidence-Based Prevention and Treatment, Dissemination and Adoption of
- Expectancies
- Fidelity of Prevention Programs
- Gateway Drugs Theory
- High-Risk Behaviors
- Information Dissemination
- Institute of Medicine Classification System
- Mentoring
- Monitoring the Future
- National Clearinghouse for Alcohol and Drug Information
- National Media Campaign
- National Outcome Measures
- National Registry of Evidence-based Programs and Practices
- National Survey on Drug Use and Health
- Prevention Education
- Prevention Evaluation
- Prevention Populations
- Prevention Resources
- Prevention Strategies
- Problem Identification and Referral
- Public Policy, Prevention
- Racial and Ethnic Minorities, Issues in Prevention
- Refusal Skills
- Risk and Protective Factor Theory
- Risk Factors for Addiction
- School-Based Prevention Programs
- Social Norms Marketing
- Social Skills Training
- Tobacco Marketing and Countermarketing
- Tobacco Master Settlement Agreement
- Underage Drinking
- Violence Prevention
- Professional Issues in Addictions
- Addiction Technology Transfer Centers
- American Society of Addiction Medicine
- Business Improvement Practices
- Centers for the Application of Prevention Technologies
- Certification and Licensing
- Clinical Supervision of Addiction Counselors
- College on Problems of Drug Dependence
- Confidentiality
- Dual Relationships
- Electronic Health Records
- Ethical Standards for Addiction Professionals
- Ethics
- Health Insurance Portability and Accountability Act
- Impaired Professionals
- Informed Consent
- International Coalition for Addiction Studies Education
- NAADAC, the Association for Addiction Professionals
- Network for the Improvement of Addiction Treatment
- Qualified Services Organization Agreements
- Single State Authorities
- State Provider Associations
- Public Policy Development
- Access to Recovery
- Center for Substance Abuse Prevention
- Center for Substance Abuse Treatment
- Comprehensive Drug Abuse Prevention and Control Act
- Decriminalization
- Demand Reduction
- Discrimination, Addicted and Recovering Individuals
- Drug Testing
- Drug-Free Schools and Communities Act
- Economic Costs of Alcohol and Drug Abuse
- Harm Reduction, Public Health
- Indian Health Services
- Insurance Parity
- Join Together
- Legal Action Center
- Legalization of Drugs
- Medical Use of Marijuana
- Moderation Approaches to Alcohol Problems
- National Council on Alcoholism and Drug Dependence
- National Drug Control Strategy
- National Epidemiologie Survey on Alcohol and Related Conditions
- National Institute of Mental Health
- National Registry of Evidence-based Programs and Practices
- Needle Exchange Programs
- Office of National Drug Control Policy
- Public Policy, Alcohol
- Public Policy, Drugs
- Public Policy, Prevention
- Public Policy, Treatment
- pulse Check
- Single State Authorities
- State Provider Associations
- Substance Abuse and Mental Health Services Administration
- Supply Reduction
- Synar Amendment
- Tobacco Master Settlement Agreement
- War on Drugs
- Recovery
- Al-Anon
- Alateen
- Alcoholics Anonymous
- Big Book, The
- Bill W.
- Cocaine Anonymous
- Double Trouble
- Dry Drunk Syndrome
- Gamblers Anonymous
- Moderation in Use
- Moderation Management
- Narcotics Anonymous
- Natural Recovery
- Peer Recovery Support Services
- Rational Recovery
- Recovery
- Recovery Community Organizations
- Recovery Community Services Program
- Recovery Schools
- Recovery Support Services
- Secular Organizations for Sobriety/Save Our Selves
- Sobriety
- Social Drinking
- Spiritual Issues
- Stigma
- Support Groups
- Twelve Steps
- Twelve-Step Recovery Programs
- Women for Sobriety
- Relapse Prevention
- Research and Evaluation Issues in Substance Abuse Prevention and Treatment
- Cannabis Youth Treatment Study
- College on Problems of Drug Dependence
- COMBINE Study
- Drug Abuse Treatment Outcome Studies
- Evidence-Based Prevention
- Evidence-Based Prevention and Treatment, Dissemination and Adoption of
- Evidence-Based Treatment
- Fidelity of Prevention Programs
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Drug Abuse
- National Institute on Drug Abuse Clinical Trials Network
- National Treatment Improvement Evaluation Study
- Prevention Evaluation
- Project MATCH
- Research Issues in Prevention
- Research Issues in Treatment
- Screening, Assessment, and Diagnosis
- Addiction Severity Index
- Alcohol Testing
- Alcohol Use Disorders Identification Test
- Alcohol-Induced Disorders
- Alcoholism
- Antisocial Personality Disorder
- Anxiety Disorders
- Assessment
- Assessment Instruments
- Borderline Personality Disorder
- CAGE Screening Instrument
- Co-Occurring Disorders
- Denial
- Depression
- Diagnosis
- Diagnostic and Statistical Manual of Mental Disorders
- Drug Abuse Screening Test
- Drug Testing
- Experimental Substance Use
- Inventory of Drinking Situations
- Michigan Alcohol Screening Test
- Post-Traumatic Stress Disorder
- Problem Oriented Screening Instrument for Teenagers
- Psychosocial History
- Screening
- Screening Instruments
- Self-Report Inventories
- Substance Abuse
- Substance Abuse Subtle Screening Inventory-3
- Substance Dependence
- Substance Use Disorders
- Substance-Induced Disorders
- Substance-Induced Withdrawal Delirium
- Timeline Followback
- Tolerance
- Urine Toxicology Testing
- Withdrawal
- Sociocultural and Historical Perspectives on Drug use
- Special Populations: Etiology, Prevention, and Treatment
- Adolescents, Substance Abuse and Treatment
- Antisocial Personality Disorder
- Anxiety Disorders
- Athletes and Drug Use
- Borderline Personality Disorder
- Children of Alcoholics
- Co-Occurring Disorders
- College Students, Alcohol Use and Abuse
- College Students, Drug Use and Abuse
- Criminal Justice Populations
- Depression
- Disabilities, Issues in Prevention and Treatment
- Elderly Populations, Treatment Issues
- Fetal Alcohol Syndrome
- Fetal Effects of Alcohol and Other Drugs
- Gay, Lesbian, Bisexual, and Transgender Issues
- Gender Issues
- Homeless, Substance Abuse and Treatment
- Maternal Drug Use
- Multiculturalism
- Post-Traumatic Stress Disorder
- Racial and Ethnic Minorities, Issues in Alcohol and Other Drug Use
- Racial and Ethnic Minorities, Issues in Prevention
- Racial and Ethnic Minorities, Issues in Treatment
- Special Populations
- Veterans, Substance Abuse and Treatment
- Welfare Reform and Substance Abuse
- Substance Abuse Health-Related Issues
- Alcohol-Related Birth Defects
- Amotivational Syndrome
- Antidepressant Drugs
- Antipsychotic Drugs
- Antiseizure Drugs
- Anxiolytic Drugs
- Attention Deficit Hyperactivity Disorder
- Blood Alcohol Concentration
- Drug Abuse Warning Network
- Fetal Alcohol Syndrome
- Fetal Effects of Alcohol and Other Drugs
- Grief, Loss, and Substance Abuse
- Health Care System and Substance Abuse
- Hepatitis C
- HIV/AIDS
- Injection Drug Use
- Insurance Parity
- Maternal Drug Use
- Medical Consequences
- Medical Use of Marijuana
- Methods of Drug Administration
- Pain Management
- Sexually Transmitted Diseases
- Suicide
- Tuberculosis
- Substance Abuse in the Workplace and School
- Treatment Theories, Research, Techniques, Strategies, and Effectiveness
- Abstinence Violation Effect
- Acamprosate
- Acceptance and Commitment Therapy
- Antabuse (Disulfiram)
- Antisocial Personality Disorder
- Anxiety Disorders
- Aversive Therapy
- Behavioral Couples Therapy
- Borderline Personality Disorder
- Brief Interventions
- Brief Strategic Family Therapy
- Buprenorphine
- Cannabis Youth Treatment Study
- CENAPS Model
- Client Engagement
- Client/Treatment Matching
- Co-Occurring Disorders
- Cognitive Behavioral Therapy
- Cognitive-Social Learning Model
- COMBINE Study
- Community Reinforcement and Family Training
- Community Reinforcement Approach
- Contingency Management
- Continuum of Care
- Counseling Approaches
- Court-Mandated Treatment
- Covert Sensitization
- Craving
- Depression
- Detoxification
- Drug Abuse Treatment Outcome Studies
- Evidence-Based Prevention and Treatment, Dissemination and Adoption of
- Evidence-Based Treatment
- Family Behavior Therapy
- Family Therapy
- Gender Issues
- Grief, Loss, and Substance Abuse
- Group Therapy and Counseling
- Harm Reduction Psychotherapy
- Inventory of Drinking Situations
- Levo-Alpha Acetyl Methadol
- Matrix Model
- Methadone Maintenance Treatment
- Minnesota Model
- Moderation Approaches to Alcohol Problems
- Moderation in Use
- Motivational Enhancement Therapy
- Motivational Interviewing
- Multidimensional Family Therapy
- Naloxone
- Naltrexone
- National Outcome Measures
- National Treatment Improvement Evaluation Study
- Nicotine Replacement Therapy
- Outpatient Treatment
- Patient Placement Criteria
- Pharmacological Approaches to Treatment
- Post-Traumatic Stress Disorder
- Project MATCH
- Public Policy, Treatment
- Qualified Services Organization Agreements
- Racial and Ethnic Minorities, Issues in Treatment
- Rapid Opioid Detoxification
- Relapse
- Relapse Prevention
- Residential Treatment
- Resistance in Treatment
- Solution-Focused Therapy
- Stages of Change Model
- Substitute Addictions
- Support Groups
- Synanon
- Therapeutic Communities
- Tobacco Cessation Programs and Treatments
- Treatment Access and Retention
- Treatment Approaches and Strategies
- Treatment Effectiveness
- Treatment Facilities
- Treatment in Jails and Prisons
- Treatment of Alcohol and Drug Use Disorders
- Treatment Plans and Treatment Planning
- Treatment Programs for Alcohol or Drug Abuse
- Treatment Settings
- Treatment, Nontraditional Approaches
- Twelve-Step Facilitation
- Veterans, Substance Abuse and Treatment
- Violence, Intimate Partner and Substance Abuse Treatment
- Loading...
Get a 30 day FREE TRIAL
-
Watch videos from a variety of sources bringing classroom topics to life
-
Read modern, diverse business cases
-
Explore hundreds of books and reference titles
Sage Recommends
We found other relevant content for you on other Sage platforms.
Have you created a personal profile? Login or create a profile so that you can save clips, playlists and searches